Research Article

Simultaneous Determination of Losartan Potassium in Pharmaceutical Products by Reversed Phase High Performance Liquid Chromatography

Raju Chandra^{1*}, Abhishek Saini¹, Ashwani Sanghi², Ganesh Pandey³, Deepak Kumar⁴

¹Department of Chemistry, Dolphin PG Institute of Biomedical and Natural Sciences, Dehradun-248001, Uttarakhand, India

²Department of Biochemistry, Dolphin PG Institute of Biomedical and Natural Sciences, Dehradun-248001, Uttarakhand, India

³School of Agriculture Science, Graphic Era University, Clement Town, Dehradun-248001, Uttarakhand, India

⁴Department of Pharmaceutical Chemistry, Dolphin PG Institute of Biomedical and Natural Sciences, Dehradun-

248001, Uttarakhand, India

Received: 23rd Dec, 17; Revised 18th Jan, 18, Accepted: 3rd Feb, 18; Available Online: 25th Feb, 18

ABSTRACT

Objective: Method validation is an important aspect for the determination of pharmaceutical products. A well validated method play an important role in the control of quality of the products. So this purpose the proposed study have been done regarding develop a validated method for losartan potassium. Methods: A reversed phase high performance liquid chromatographic method used on isocratic mode. Results: The chromatographic separation of losartan potassium was obtained using a C_{18} column by isocratic elusion at the 25^oC column temperature. The green solvent (methanol and water, 30:70 v/v) was used as a mobile phase. The analysis was performed at the flow rate 1.0 ml/min. A well defined peak was detected at 273 nm. The retention time of acive engredients losartan potassium was obtained in 7 min. The limit of detection and limit of quantification was calculated 0.03 and 0.09 µg/ml, respectively. A Good results was obtained with respect to linearity R²=0.998. The mean recoveries in inter-day and intra-day were calculated 98.85 % and 99.4 % with CV value 1.38 and 2.24 respectively. Conclusion: The method was validated according to ICH guidelines. This method is very efficient for the analysis of losartan potassium at 25 ^oC.

Keywords: RP-HPLC, Losartan potassium, recoveries.

INTRODUCTION

Losartan potassium generally used in the treatment of hypertention, heart failureand heart attacks and it is also prevent to the complications of diabetes. It is angiotensin converting enzyme inhibitor. Chemically it is 2-butyl-4-chloro-1-{[2-(1H-tetrazol-5-yl]methyl}-1H-Imidazol-5-yl]methanol and the empirical formula is $C_{22}H_{22}CIKN_6O^{1,2}$.

The literature survey has been shown various analytical methods for the estimation of losartan potassium active ingredients using high performance liquid chromatography methods³⁻⁵. The proposed study has been done according to ICH guidelines⁶⁻⁸.

MATERIALS AND METHODS

Preparation of mobile phase

A methanol / water mobile phase was prepared in the ratio of methanol: water (30:70, v/v). The mobile phase were filtered through a $0.45\mu m$ nylon membrane and degassed by sonication.

Preparation of Losartan potassium stock solution

A 100 $\mu g/ml$ stock solution was prepared, 10 mg losartan potassium was mixed with methanol and make up it to 100



Fig.1: Chemical structure Losartan Potassium

ml. The stock solution was filtered with 0.45 µm nylon filter membrane and degassed by sonication. *Preparation of sample solution*

The 10 tablets of Losartan potassium were weight and crushed by mortar and pestle. The crushed tablets were mixed well, and then an equivalent amount of 10 mg was transferred in to a small conical flask and extracted with methanol ratio. The extract was filtered into a 100 ml

S.	Parameter	Mean	CV in
NO.		value	Percentage
			(%)
1.	Retention	7.1	2.032
	Time		
2.	Tailing factor	0.86	0.310
3.	Resolution	1.561	0.72
	factor		
4.	Theoretical	658.004	3.788
	factor		

Table No. 1. Results for system suitability

CV = coefficient variance

Table No. 2. Results for linearity

S.NO.	Parameter	RP-HPLC		
1.	Correlation factor	10-50µg/ml		
2.	Liner equation	13852X-43291		
3.	Regression	0.997		
	coefficient (R ²)			

volumetric flask and the volume make up to 100 ml. Achieved aliquots was covered the working concentration range 100 μ g/ml.

Preparation of calibration curve

A calibration curve was constructed to evaluation the linearity. The calibration curve was plotted, using average peak area ratio and different drug concentrations (µg/ml). A total volume of 10 ml was maintained with mobile phase methanol and water. These different serial dilutions were filtered through a 0.45µm nylon membrane and sonicate. The each solution of 20 µl was injected into the column in thrice. The calibration curve was obtained by plotting peak area versus concentration.

Method validation

The describe method was validated according to ICH guidelines with respect to following parameters.

Linearity

As per ICH guidelines the linearity of an analytical procedure is its ability to obtain test results which are directly proportional to the concentration of analyte in the sample.

Linearty can be calculated by using following equation as per ICH guidelines.

y = mx + b

Where 'm' and 'b' are the constants, the constants 'm' determines the slop or gradient of that line and the constant 'b' determines the point at which the line crosses the yaxis, otherwise known as the y- intercept.

Specificity

It is the ability to assess unequivocally the analyte in the presence of components which may be expected to be present.

Specificity can be calculated by using following equation as per ICH guidelines.

Number of true negatives

 $Specificity = \frac{1}{Number of true negatives + number of false positives}$ Specificity was determined with excipients of formulated tablets. An equivalent weight was taken and solution

Table No. 3 Limit of detection (LOD) and limit of

quantification	(LUQ)	
S.NO.	Parameters	RP-HPLC
1.	Limit of Detection	0.03 µg/ml
	(LOD)	
2.	Limit of Quantification	0.09 µg/ml
	(LOQ)	

prepared similarly to the sample solution. The prepared solution was determined as per the describe method. Accuracy

The accuracy of the proposed methods was checked by recovery studies. The accuracy measured by addition of standard drug solution to reanalyzed sample solution at three different concentration levels within the range of linearity.

Accuracy can be calculated by using following equation as per ICH guidelines.

 $%Recovery = \frac{Peak Area of the Drug in standard}{Peak Area of the Drug in sample Mixture}$ $- \times 100$

System suitability test

The reproducibility of sample was checked of the sample to measurement of peak area and was carried out using three replicates of same concentrations of standard and sample, respectively.

Limit of detection (LOD) & limit of quantification(LOQ) Detection of limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value. The limit of detection can be calculated using following equation as per ICH guidelines.

 $LOD = 3.3 \times \frac{Standard deviation of the Peak Area of the drug}{Slope of the Corresponding Calibration Curve}$ Limit of quantification can be calculated using following equation as per ICH guidelines.

 $LOQ = 10 \times \frac{Standard\ deviation\ of\ the\ Peak\ Area\ of\ the\ drug}{Slope\ of\ the\ Corresponding\ Calibration\ Curve}$

To determine the limit of detection (LOD) and limit of quantification (LOQ) prepared three replications of low concentrations serial dilution of mixed standard of losartan potassium from the standard stock solution.

RESULTS AND DISCUSSION

Selection of mobile phase and Chromatographic conditions

It is a basic need of high performance liquid chromatography (HPLC). The mobile phase have been selected to check the mobile phase at various composition with the solvent of HPLC grade water and methanol 70:30, 60:40, 50:50, 40:60 and 30:70 (v/v). The mobile phase methanol and water in the ratio of 30:70 (v/v) are selected, thus at this mobile phase was obtained a suitable retention time and peak area of the active ingredients. The separation achieved on reversed phase C_{18} column with the wave length 273 nm.

Specificity

The specificity of the method was determined by checking the interference with the components from placebo, there is no interference was observed for any of the components

Table No 4	4 Results	of inter	day recovery	experiment
1 4010 1 10.	r. itesuits	or miter	uay recovery	experiment

Drug adde d in µg	Recover y in µg	Recover y in %	Mea n %	CV %
10	9.88	98.8		
20	20.05	100.25	98.8 5	1.3
30	29.25	97.5	5	0
	Drug adde d in <u>µg</u> 10 20 30	Drug adde d in Recover y in μg μg - 10 9.88 20 20.05 30 29.25	Drug adde d in Recover y in μg Recover y in % μg - - 10 9.88 98.8 20 20.05 100.25 30 29.25 97.5	Drug adde d in Recover y in μg μg Recover y in % Mea n % 10 9.88 98.8 20 20.05 100.25 98.8 5 30 29.25 97.5

Table No. 5. Results of intraday recovery experiment						
S.	Drug	Recover	Recovery	Mean	CV	
NO.	added	y in µg	in %	%	%	
	in µg					
1.	10	9.9	99			
2.	20	20.5	102.5	99.94	2.24	
3.	30	29.5	98.33			

CV = coefficient variance

like excipients.

System stability test

System suitability test was performed to stabilization the chromatographic conditions. The test was performed by injecting the standard mixture in thrice replications. The various parameters Retention time (R_t), Tailing Factor (T_f), Resolution Factor (R_f) and Theoretical plates (T_p) were computed. All parameters were statistically calculated. The CV% of the retention time (R_t), tailing factor (T_f), resolution factor (R_f) and theoretical plates (T_p) were reported 2.032, 0.310, 0.72, and 3.788 which were shown in the following table⁹⁻¹⁰.

The calculated CV % value of all parameters are less than 10 (<10), thus all CV% values are significant¹¹.

Linearity

The detector response for the proposed method determined to be linear over the range. The five concentration levels 10, 20, 30, 40 and 50 μ g/ml were prepared and injected. The calibration curve was plotted between drug concentration and average peak area for. The linearity of the method was calculated by linear regression analysis.

The correlation range was determined $10-50 \ \mu g/ml$. The regression coefficient was calculated 0.997. Hence the above calculated data are showing that the detector response is linear.

Limits of Detection (LOD) and Limit of Quantification (LOQ)

The limit of detection (LOD) and limit of quantification (LOQ) were determined by calculating the signal to noise ratio for losartan potassium. The limit of detection (LOD) and limit of quantification value was found 0.03μ g/ ml and 0.09μ g/ ml.

Accuracy

The accuracy of the method was determined by recovery method at the three concentration levels $(10, 20 \text{ and } 30 \mu g)$. The recovery study has been done on the basis of inter day

and intraday. The results of inter day recoveries was calculated 98.85 % with CV value 1.38 % and in intraday calculated 99.94 % with CV value 2.24%.

The CV % in both experiments interday and intraday was estimated less than 10 which indicated that the experiment is significant. Thus the recovery results were shown good co-relation with adding losartan potassium drug content. Thus, experimental method was success for the quantitative determination of Losartan potassium¹².

CONCLUSION

The proposed study has been done in isocratic mode with reversed phase-high performance liquid chromatography method. The developed method was linear as shown the calculated value (R^2) 0.997. The limit of detection and limit of quantification was calculated 0.03 and 0.09 µg/ml. The inter-day and intra-day average percentage recovery at three concentration levels were estimated 98.85 % and 99.94 % with the coefficient variation percentage 1.38 (<10) and 2.24 (<10). Therefore, this method is very efficient for the estimation of drug content from pharmaceutical products.

REFERENCES

- 1. Munafo AY, Christen J, Nussberger LY, Shum RM, Borland RJ, Lee Waeber J, Biollaz HR Brunner. Clinical Pharmacology Therapeutics 1992; 513-521.
- 2. Smith RD, Chiu AT, Wong PC, Herbin WF, Timmermans PBMWM. Annual Review of Pharmacology and Toxicology. 1992; 32: 135-65.
- 3. Kathiresan K, Gothandaraman S, Swamival M, Manickam S, Mathan K, Manavalam R. Analytical method development and validation of losartan potassium tablet by RP-HPLC. Rasayan J Chem, 2008; 3: 521-525.
- Jagadeeswararao V, Vasanth PM, Ramesh T, Ramesh M. analytical method development and validation of losartan potassium and hydrochlorothiazide in combined dosage form by RP-HPLC. International Journal of ChemTech research, 2013; 5: 3007-3014.
- Khan M, Rizwan S, Anis TAK. Simultaneous determination and method development for assay of losrtan potassium and hydrochlorotiazide drugs in solid dosage form by RP-HPLC. Indian Journal of Pharmaceutical Science & Research, 2012; 2: 42-45.
- 6. International Conference on Harmonization, Validation of Analytical Procedures: Text and Methodology, Geneva, Switzerland, 2005, ICH Q2 (R1).
- 7. ICH Harmonized Triplicate Guidelines ICH, Validation of Analytical Procedures: Consensus Guidelines, 1994, ICH Q2A.
- ICH Harmonized Triplicate Guidelines, Validation of Analytical Procedures: Methodology, Consensus Guidelines, 1996, ICH Q2B.
- 9. Raju C, Manisha P, Harchan S, Deepak K, Ashwani S. Development and validation of a reversed phase-high performance liquid chromatography method for the quantitative estimation of ramipril drug content from

formulated dosage form. International Journal of Drug Delivery Technology 2016; 6(3); 64-67.

- 10. Raju C, Ashwani S, Deepak K, Augustin KB. Development and validation a RP-HPLC method: Application for the quantitative determination of quetiapine fumarate from marketed bulk tablets. Journal of Chemical and Pharmaceutical Research, 2016; 8(1):142-146.
- 11. Raju C, Sanjay S, Keshav DS, Md NA, Sujeet K. Quantity based quality estimation of diclofenac sodium

by reversed phase-high performance liquid chromatography separation method from formulated tablets. International Journal of Comprehensive Pharmacy, 2013; 4(5): 1-3.

12. Raju C, Keshav DS. Quantitative determination of paracetamol and caffeine from formulated tablets by reversed phase-hplc separation technique. International Journal of Chromatographic Science, 2013; 3(2): 31-34.